Regenxbio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
RGNX Nasdaq 8731 https://regenxbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Regenxbio Inc

Analysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest Results - May 11th, 2024 12:17 pm
Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts - May 10th, 2024 6:30 pm
REGENXBIO to Participate in Upcoming Investor Conferences - May 10th, 2024 11:05 am
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript - May 9th, 2024 7:53 pm
Q1 2024 Regenxbio Inc Earnings Call - May 9th, 2024 11:11 am
Regenxbio Inc (RGNX) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress and Robust ... - May 9th, 2024 7:46 am
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates - May 8th, 2024 9:40 pm
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights - May 8th, 2024 8:05 pm
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights - May 1st, 2024 11:05 am
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit - Apr 24th, 2024 11:05 am
REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures - Apr 17th, 2024 10:57 am
REGENXBIO Sees Positive Results For Macular Degeneration Therapy - Mar 28th, 2024 5:09 pm
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD - Mar 28th, 2024 11:05 am
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days - Mar 27th, 2024 8:05 pm
Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares - Mar 18th, 2024 11:00 pm
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? - Mar 13th, 2024 12:00 pm
Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares - Mar 8th, 2024 6:29 am
Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates - Mar 7th, 2024 7:03 pm
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants - Mar 7th, 2024 4:20 am
REGENXBIO Announces Proposed Public Offering of Common Stock - Mar 6th, 2024 9:10 pm